Ryan Madder, MD
Interventional Cardiology · Royal Oak, MINPI 1306968763
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $161,991 of the $230,950 with a category attached, or 70.1%. 18 manufacturers reported payments, led by Abbott at 27.4% of the total. 2025 is the largest year on record at $76,855, more than ten times the $1,956 reported in 2019. Among interventional cardiology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $777.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$63K
- Siemens Medical Solutions USA, Inc.$61K
- Boston Scientific$37K
- Medtronic$35K
- Spectrawave, Inc$26K
- Gentuity, LLC$5K
- plus $5K from 12 others
Across 6 payments — averaging $1294.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$8K
What the payments were for
- Consulting fees$161,99170%
- Speaking & faculty fees$33,23314%
- Travel & lodging$23,25410%
- Food & beverage$12,4735%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 88 | $63,248 |
| Siemens Medical Solutions USA, Inc. | 50 | $60,824 |
| Boston Scientific | 33 | $36,731 |
| Medtronic | 64 | $34,823 |
| Spectrawave, Inc | 21 | $25,882 |
| Gentuity, LLC | 5 | $4,579 |
| Corindus Inc. | 8 | $1,562 |
| Medicure Pharma Inc. | 1 | $1,500 |
| Shockwave Medical, Inc | 6 | $767 |
| Abiomed | 10 | $574 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $118 |
| Philips North America LLC | 1 | $114 |
| Livanova USA, Inc. | 1 | $79 |
| Stryker | 2 | $60 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Cathworks, Inc. | 1 | $29 |
| Novartis | 1 | $15 |
| Cordis US CORP. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$31,123
- OPTIS$28,187
- HyperVue Imaging System$23,696
- CorPath Imaging System$18,828
- GENERAL VASCULAR ACCESS$18,301
- CorPath GRX$9,436
- RESOLUTE ONYX$9,313
- SYMPLICITY G3$8,688
- GENERAL BALLOONS$5,938
- Starlight Imaging Catheter$4,671
- Gentuity HF-OCT Imaging System$4,473
- Vis-Rx$4,473
- AVVIGO Guidance System$4,143
- OPTICROSS$3,125
- General - CT_IC$2,344
- Acute cardiovascular care$1,500
- SUPERA$1,000
- XIENCE SIERRA$1,000
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$631
- COROFLOW$513
How this compares
$230,950 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $106,042 |
| XareltoRivaroxaban | 29 | $42,526 |
| BrilintaTicagrelor | 34 | $21,741 |
| Repatha SureclickEvolocumab | 15 | $13,341 |
| FarxigaDapagliflozin Propanediol | 11 | $11,109 |
| EntrestoSacubitril/Valsartan | 12 | $10,869 |
| Rosuvastatin Calcium | 180 | $4,110 |
| Metoprolol Succinate | 154 | $4,079 |
| Atorvastatin Calcium | 146 | $3,442 |
| Ezetimibe | 75 | $2,563 |
| Ranolazine ErRanolazine | 14 | $1,975 |
| Carvedilol | 81 | $1,532 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 54 | $1,238 |
| Amlodipine Besylate | 85 | $957 |
| Lisinopril | 74 | $878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $10,86912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Royal Oak
- Lakshmi RaoRoyal Oak$26K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.